China Pharma Holdings Stock Probability of Future Stock Price Finishing Over 21.12
| CPHI Stock | USD 0.20 0.01 5.26% |
China |
China Pharma Target Price Odds to finish over 21.12
The tendency of China Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 21.12 or more in 90 days |
| 0.20 | 90 days | 21.12 | close to zero percent |
Based on a normal probability distribution, the odds of China Pharma to move over $ 21.12 or more in 90 days from now is close to zero percent (This China Pharma Holdings probability density function shows the probability of China Stock to fall within a particular range of prices over 90 days) . Probability of China Pharma Holdings price to stay between its current price of $ 0.20 and $ 21.12 at the end of the 90-day period is about 78.19 .
Given the investment horizon of 90 days China Pharma Holdings has a beta of -0.97 suggesting Additionally China Pharma Holdings has an alpha of 0.3402, implying that it can generate a 0.34 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). China Pharma Price Density |
| Price |
Predictive Modules for China Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as China Pharma Holdings. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.China Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. China Pharma is not an exception. The market had few large corrections towards the China Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold China Pharma Holdings, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of China Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.34 | |
β | Beta against Dow Jones | -0.97 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | 0.01 |
China Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of China Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for China Pharma Holdings can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| China Pharma had very high historical volatility over the last 90 days | |
| China Pharma has some characteristics of a very speculative penny stock | |
| China Pharma has high likelihood to experience some financial distress in the next 2 years | |
| China Pharma Holdings currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 2.63, implying the company greatly relies on financing operations through barrowing. China Pharma Holdings has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about China Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 7.01 M. Net Loss for the year was (3.08 M) with profit before overhead, payroll, taxes, and interest of 349.27 K. | |
| China Pharma Holdings currently holds about 2.24 M in cash with (699.69 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| China Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of China Pharma shares are held by company insiders | |
| Latest headline from news.google.com: Investors in China Medical System Holdings have unfortunately lost 31 percent over the last three years - Simply Wall St |
China Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of China Stock often depends not only on the future outlook of the current and potential China Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. China Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.4 M | |
| Cash And Short Term Investments | 1.4 M |
China Pharma Technical Analysis
China Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. China Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of China Pharma Holdings. In general, you should focus on analyzing China Stock price patterns and their correlations with different microeconomic environments and drivers.
China Pharma Predictive Forecast Models
China Pharma's time-series forecasting models is one of many China Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary China Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about China Pharma Holdings
Checking the ongoing alerts about China Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for China Pharma Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| China Pharma had very high historical volatility over the last 90 days | |
| China Pharma has some characteristics of a very speculative penny stock | |
| China Pharma has high likelihood to experience some financial distress in the next 2 years | |
| China Pharma Holdings currently holds 4.63 M in liabilities with Debt to Equity (D/E) ratio of 2.63, implying the company greatly relies on financing operations through barrowing. China Pharma Holdings has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about China Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 7.01 M. Net Loss for the year was (3.08 M) with profit before overhead, payroll, taxes, and interest of 349.27 K. | |
| China Pharma Holdings currently holds about 2.24 M in cash with (699.69 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.04. | |
| China Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of China Pharma shares are held by company insiders | |
| Latest headline from news.google.com: Investors in China Medical System Holdings have unfortunately lost 31 percent over the last three years - Simply Wall St |
Check out China Pharma Backtesting, China Pharma Valuation, China Pharma Correlation, China Pharma Hype Analysis, China Pharma Volatility, China Pharma History as well as China Pharma Performance. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.